Companies Applied Therapeutics, Inc.
Applied Therapeutics (APLT): executive pay, fiscal 2024
Free brief. Every figure links to the company’s own filing.
Email me Applied Therapeutics, Inc.’s executive pay brief as a PDF
It arrives in about 2 minutes, with every figure cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $1,053,846FY2024
CEO total pay was $1,053,846 in fiscal 2024; the brief holds no earlier figure for this CEO.
FY2024: salary $530,625 · bonus $225,600 · stock awards $153,000 · option awards $132,000
Order APLT
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Shoshana Shoshana | $646,528 | $0 | $0 | $28,966 | $0 | $0 | $3,098,139 | $3,773,633 |
| Shendelman, Ph.D. Former President, Chief Executive Officer and Secretary | ||||||||
| John Johnson | 31,570 | 0 | 1,020,000 | 1,790,000 | 0 | 0 | 0 | 2,841,570 |
| Executive Chairman | ||||||||
| Dale Hooks | 375,852 | 121,052 | 1,548,000 | 0 | 0 | 0 | 14,676 | 2,059,580 |
| Chief Commercial Officer | ||||||||
| Les Funtleyder | 530,625 | 225,600 | 153,000 | 132,000 | 0 | 0 | 12,621 | 1,053,846 |
| Interim Chief Executive Officer and Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2024 total | FY2023 total | FY2022 total | Δ FY2023→2024 |
|---|---|---|---|---|
| Shoshana Shoshana | $3,773,633 | $9,493,213 | — | ↓ −5,719,580 |
| John Johnson | 2,841,570 | — | — | — |
| Dale Hooks | 2,059,580 | — | — | — |
| Les Funtleyder | 1,053,846 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
Our objective is to provide a market-based executive compensation program that aligns the interests of our named executive officers with our stockholders and incentivizes them to achieve our key business objectives. We consider compensation for comparable positions in the market, historical compensation levels, individual performance, and our desire to motivate executives to achieve short- and long-term results that are in the best interests of our stockholders.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | AON Radford Global Compensation Consulting |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2024
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Les Funtleyder | OPTION | 2024-12-19 | — | — | 150,000 | — | $132,000 |
| John Johnson | OPTION | 2024-12-19 | — | — | 2,000,000 | — | 1,790,000 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Les Funtleyder | $0 | $0 | $132,000 | 0.0% |
| John Johnson | 0 | 0 | 1,790,000 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2024
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Les Funtleyder | RSU | 137,500 | — | $118,250 |
| Les Funtleyder | RSU | 150,000 | — | 129,000 |
| Les Funtleyder | Option | 150,000 | 1.02 | — |
| Dale Hooks | RSU | 300,000 | — | 258,000 |
| John Johnson | RSU | 500,000 | — | 430,000 |
| John Johnson | PSU | 500,000 | — | 430,000 |
| John Johnson | Option | 1,000,000 | 1.02 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Stacy J. KanterIndependent · Audit (Chair) | $65,000 | $202,500 | — | — | — | $267,500 |
| Jay S. Skyler, M.D., MACPIndependent · Audit · Compensation (Chair) | 65,000 | 202,500 | — | — | — | 267,500 |
| Teena Lerner, Ph.DIndependent · Lead Independent Director · Audit · Compensation | 62,500 | 202,500 | — | — | — | 265,000 |
| Joel S. MarcusIndependent · Departed during FY | 58,084 | 202,500 | — | — | — | 260,584 |
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2024 |
|---|---|
| Cash retainers and fees | $250,584 |
| Equity awards (grant-date value) | $810,000 |
| All other compensation | $0 |
| Total cost of the board | $1,060,584 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Applied Therapeutics as a peer
Companies that benchmark against APLT
2 companies name APLT as a compensation peer
- DiaMedica Therapeutics Inc.DMACFY2025
- Savara IncSVRAFY2025
Each company listed discloses APLT in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named APLT in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Applied Therapeutics, Inc. | 2024 | Les Funtleyder | $530,625 | $153,000 | $132,000 | $0 | $1,053,846 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
No say-on-pay vote is on file for this company.
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (14 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Shoshana Shoshana. DEF 14A, filed 2025-04-28. Section “Executive Compensation”. As printed: 3,773,633. View filing ↗
- Section 01, John Johnson. DEF 14A, filed 2025-04-28. Section “Executive Compensation”. As printed: 2,841,570. View filing ↗
- Section 01, Dale Hooks. DEF 14A, filed 2025-04-28. Section “Executive Compensation”. As printed: 2,059,580. View filing ↗
- Section 01, Les Funtleyder. DEF 14A, filed 2025-04-28. Section “Executive Compensation”. As printed: 1,053,846. View filing ↗
- Section 03, Les Funtleyder OPTION. DEF 14A, filed 2025-04-28. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, John Johnson OPTION. DEF 14A, filed 2025-04-28. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 08, Stacy J. Kanter. DEF 14A, filed 2025-04-28. Section “Director Compensation”. As printed: 267,500. View filing ↗
- Section 08, Jay S. Skyler, M.D., MACP. DEF 14A, filed 2025-04-28. Section “Director Compensation”. As printed: 267,500. View filing ↗
- Section 08, Teena Lerner, Ph.D. DEF 14A, filed 2025-04-28. Section “Director Compensation”. As printed: 265,000. View filing ↗
- Section 08, Joel S. Marcus. DEF 14A, filed 2025-04-28. Section “Director Compensation”. As printed: 260,584. View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 250,584 + equity 810,000 + all other 0 = 1,060,584, summed across the director compensation table rows.
- Applied Therapeutics, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2025-04-28. CEO total compensation as printed in Applied Therapeutics, Inc.'s own proxy. As printed: 1,053,846. View filing ↗